Zevra Therapeutics, Inc. (ZVRA)

In the past six months, ZVRA's stock price has trended down. Key events impacting the stock include a financial restatement disclosure in March 2024, a debt refinancing in April 2024, and the sale of a Priority Review Voucher (PRV) in April 2025. The company reported a quarterly loss of $0.06 per share in Q1 2025, surpassing estimates, and revenues of $20.4 million, exceeding estimates by 29.12%. Zevra reported Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million. The company reported Q3 2025 net revenue of $26.1 million, primarily from MIPLYFFA net revenue of $22.4 million and decided to scale back sales and marketing efforts for OLPRUVA while evaluating options for the product.

Zevra Therapeutics operates in the rare disease therapeutics space, which may not exhibit strong product demand seasonality. Historical data suggests that buying ZVRA stock in June has the highest probability of a positive return, while March has the lowest. This seasonal timeframe aligns with the broader Healthcare sector's period of seasonal strength, which typically runs from April 25 to December 4.

Zevra Therapeutics, Inc. is a commercial-stage company focused on addressing unmet needs in rare disease treatments within the Biotechnology sector. The company develops and commercializes therapies for conditions with limited treatment options, utilizing its Ligand Activated Technology (LAT) platform. Key commercial products include MIPLYFFA for Niemann-Pick disease type C, OLPRUVA for urea cycle disorders, and AZSTARYS for ADHD, from which Zevra derives royalties. The pipeline includes KP1077 in clinical trials for idiopathic hypersomnia and narcolepsy, and Celiprolol in Phase 3 trials for vascular Ehlers-Danlos syndrome.

Zevra Therapeutics, Inc. is headquartered in Celebration, Florida, USA, with corporate offices in Boston, USA, and Frederiksberg, Denmark. The company has expanded its global reach through a distribution agreement with Uniphar to provide MIPLYFFA to patients outside of the U.S. and Europe.

Zevra Therapeutics' brand reputation was impacted by a financial restatement disclosure in March 2024, leading to an investigation by Holzer & Holzer, LLC. Despite this, analyst ratings generally indicate a "Moderate Buy" or "Strong Buy" consensus, and the company has highlighted strong performance of its product MIPLYFFA.

Zevra Therapeutics, Inc. is predominantly owned by institutional shareholders, who hold 70.82% of the stock, while insiders own 22.18%, and retail investors hold 6.99%. Major institutional owners include BlackRock, Inc., Woodline Partners LP, AIGH Capital Management LLC, Vanguard Group Inc, Adage Capital Partners Gp, L.l.c., Nantahala Capital Management, LLC, Fmr Llc, and State Street Corp. The largest individual shareholder is Delaware Street Capital Master Fund LP, owning 4.10 million shares, representing 7.28% of the company.